Trial Profile

A pivotal Phase 3 trial of BIV201 (continuous infusion terlipressin) in ascites patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2024 According to an BioVie media release, Company is also continuing partnering discussions for bezisterim's geographic rights, and plans to commence an ascites Phase 3 trial for BIV201 (continuous infusion terlipressin) upon identifying a suitable partner.
11 Mar 2024 According to an BioVie media release, this trial is in preparation following FDA feedback with guidance on development path. The program is delayed pending partnership funding.
13 Nov 2023 According to a BioVie media release, this trial is expect to initiate in Q2 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com